Measuring the impact of risk communications: Robust analytical approaches are key

Affiliations

Comment

Peter Arlett. Br J Clin Pharmacol. 2020 Apr.

. 2020 Apr;86(4):635-636.

doi: 10.1111/bcp.14222. Epub 2020 Feb 16.

¹ Pharmacovigilance and Epidemiology Department, European Medicines Agency, Amsterdam, The Netherlands.

No abstract available

Keywords: impact research; pharmacovigilance; risk communication; risk management.

Conflict of interest statement

The author has no conflicts of interest to declare.

Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis.
Weatherburn CJ, Guthrie B, Dreischulte T, Morales DR. Weatherburn CJ, et al. Br J Clin Pharmacol. 2020 Apr;86(4):698-710. doi: 10.1111/bcp.14104. Epub 2019 Dec 16. Br J Clin Pharmacol. 2020. PMID: 31465123 Free PMC article.

1. Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug Saf. 2017;40(10):855‐869. - PMC - PubMed
1. Wisniewski AF, Bate A, Bousquet C, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39(6):469‐490. 10.1007/s40264-016-0405-1 - DOI - PMC - PubMed
1. Arlett P, Portier G, de Lisa R, et al. Proactively managing the risk of marketed drugs: experience with the EMA pharmacovigilance risk assessment committee. Nat Rev Drug Discov. 2014;13(5):395‐397. - PubMed
1. Smith MY, Russell A, Bahri P, et al. The RIMES statement: a checklist to assess the quality of studies evaluating risk minimization programs for medicinal products. Drug Saf. 2018. Apr;41(4):389‐401. - PMC - PubMed
1. Pacurariu A, Plueschke K, McGettigan P, et al. Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. BMJ Open. 2018;8(11):e023090corr1 10.1136/bmjopen-2018-023090corr1 - DOI - PMC - PubMed